Descriptions

Ror2 (receptor tyrosine kinase-like orphan receptor 2, an unconventional Wnt receptor) may be involved in the early formation of chondrocytes and may be required for cartilage and growth plate development. Ror2 autoinhibition combines several elements. Its activation loop occludes the substrate- and ATP-binding sites and the interactions between the activation loop and αC helix in the N-terminal lobe stabilizes the autoinhibited state of Ror2.

Autoinhibitory domains (AIDs)

Target domain

16-138 (Small GTP-binding protein domain)

Relief mechanism

Ligand binding

Assay

Accessory elements

No accessory elements

Autoinhibited structure

Activated structure

5 structures for P40616

Entry ID Method Resolution Chain Position Source
1UPT X-ray 170 A A/C/E/G 15-181 PDB
4DCN X-ray 301 A A/B 14-179 PDB
5EE5 X-ray 228 A B 15-181 PDB
5J5C X-ray 340 A A 16-181 PDB
AF-P40616-F1 Predicted AlphaFoldDB

95 variants for P40616

Variant ID(s) Position Change Description Diseaes Association Provenance
rs1351342399 3 G>R No gnomAD
rs745925566 4 F>V No ExAC
gnomAD
rs1565816628 5 F>L No Ensembl
rs199647502 8 I>M No 1000Genomes
ExAC
TOPMed
gnomAD
rs1444439963 8 I>V No TOPMed
gnomAD
rs889507227 15 T>S No Ensembl
rs1441918855 16 R>Q No gnomAD
rs1351775004 18 M>I No gnomAD
rs1871427614 18 M>T No TOPMed
gnomAD
COSM259508 19 R>K Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] No NCI-TCGA Cosmic
TCGA novel 25 L>* Variant assessed as Somatic; HIGH impact. [NCI-TCGA] No NCI-TCGA
TCGA novel 31 T>I Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] No NCI-TCGA
rs747900626 33 I>V No ExAC
gnomAD
COSM4414439 35 Y>C Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] No NCI-TCGA Cosmic
rs1409129413 36 R>K No gnomAD
rs997604444 38 Q>H No Ensembl
TCGA novel 41 E>* Variant assessed as Somatic; HIGH impact. [NCI-TCGA] No NCI-TCGA
rs1871426153 46 I>T No TOPMed
rs1871426258 46 I>V No TOPMed
rs866509393 47 P>H No Ensembl
TCGA novel 50 G>E Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] No NCI-TCGA
rs1871343910 51 F>V No Ensembl
rs759551539 55 T>M No ExAC
gnomAD
rs774423552 57 T>M No ExAC
gnomAD
rs1482235542 57 T>S No gnomAD
rs1871343274 58 Y>* No TOPMed
rs778166981 58 Y>C No Ensembl
rs778166981 58 Y>F No Ensembl
rs1318906358
COSM3416380
59 K>E Variant assessed as Somatic; MODERATE impact. large_intestine [NCI-TCGA, Cosmic] No NCI-TCGA Cosmic
cosmic curated
NCI-TCGA
gnomAD
rs748085890 60 N>H No ExAC
gnomAD
rs2121120858 61 L>F No Ensembl
COSM933961 62 K>T Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] No NCI-TCGA Cosmic
rs374438987 65 V>I No ESP
ExAC
gnomAD
rs374438987 65 V>L No ESP
ExAC
gnomAD
rs867932766 66 W>* No Ensembl
rs200228067 71 Q>* No 1000Genomes
ExAC
TOPMed
gnomAD
rs1565815927 72 T>A No Ensembl
COSM691648 83 S>* Variant assessed as Somatic; HIGH impact. [NCI-TCGA] No NCI-TCGA Cosmic
rs1871295092 85 T>R No Ensembl
TCGA novel 86 D>Y Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] No NCI-TCGA
TCGA novel 88 V>A Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] No NCI-TCGA
rs1266416513 88 V>I No TOPMed
gnomAD
rs767639040 95 C>G No ExAC
gnomAD
rs1871294615 95 C>Y No Ensembl
rs774354950 97 R>* No ExAC
gnomAD
rs774354950 97 R>G No ExAC
gnomAD
rs1448134752 97 R>Q No gnomAD
COSM4877872 98 D>G Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] No NCI-TCGA Cosmic
rs763085137 99 R>* No ExAC
gnomAD
COSM3416379
rs1033216289
99 R>Q Variant assessed as Somatic; MODERATE impact. large_intestine [NCI-TCGA, Cosmic] No NCI-TCGA Cosmic
cosmic curated
Ensembl
NCI-TCGA
TCGA novel 100 I>L Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] No NCI-TCGA
rs1295096319 101 G>A No gnomAD
rs1295096319 101 G>D No gnomAD
rs1456165523 103 S>A No gnomAD
rs1337723460 103 S>Y No TOPMed
gnomAD
rs1871293520 104 K>E No gnomAD
COSM3398252 104 K>N Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] No NCI-TCGA Cosmic
TCGA novel 105 S>L Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] No NCI-TCGA
rs1441455563 108 V>A No gnomAD
COSM933960
rs1159806718
108 V>I Variant assessed as Somatic; MODERATE impact. endometrium [NCI-TCGA, Cosmic] No NCI-TCGA Cosmic
cosmic curated
NCI-TCGA
gnomAD
rs1871292475 111 L>V No TOPMed
rs745606476 116 L>P No ExAC
TOPMed
gnomAD
COSM4037997 117 R>G Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] No NCI-TCGA Cosmic
rs770515193 118 K>R No ExAC
gnomAD
rs1871159041 122 V>M No gnomAD
rs1871158729 125 A>S No Ensembl
rs1871158598 125 A>V No Ensembl
rs1019490890 128 Q>* No Ensembl
rs777262033 130 M>V No ExAC
TOPMed
gnomAD
rs756672768 132 Q>R No ExAC
gnomAD
rs977321395 137 S>A No TOPMed
gnomAD
rs2121104863 138 E>D No Ensembl
rs199895049 139 M>I No ESP
ExAC
TOPMed
gnomAD
rs867593405 140 A>T No Ensembl
rs751810522 141 N>D No ExAC
TOPMed
gnomAD
rs1428802587 144 G>A No TOPMed
gnomAD
rs1428802587 144 G>E No TOPMed
gnomAD
rs1479033109 146 P>L No TOPMed
gnomAD
rs766628640 146 P>S No ExAC
TOPMed
gnomAD
rs1261457288 150 D>H No gnomAD
COSM2063365
rs1429217176
151 R>Q Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] No NCI-TCGA Cosmic
NCI-TCGA
TOPMed
rs1162530360 152 K>R No Ensembl
rs1193650336 156 F>L No gnomAD
rs1871156183 157 K>N No TOPMed
rs1443494961 158 T>M No gnomAD
rs981097493 161 T>A No TOPMed
gnomAD
rs1871155739 163 G>A No Ensembl
COSM278976 165 G>D Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] No NCI-TCGA Cosmic
rs1871155507 165 G>S No Ensembl
rs750585373 169 A>S No ExAC
gnomAD
COSM430163 170 M>V Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] No NCI-TCGA Cosmic
rs1352049388 172 W>* No gnomAD
rs900100900 178 K>E No Ensembl
rs761389991 181 Q>P No ExAC
TOPMed
gnomAD
COSM3810785 182 Q>Y Variant assessed as Somatic; HIGH impact. [NCI-TCGA] No NCI-TCGA Cosmic

No associated diseases with P40616

14 regional properties for P40616

Type Name Position InterPro Accession
domain PB1 domain 25 - 107 IPR000270
domain Protein kinase domain 253 - 521 IPR000719
domain AGC-kinase, C-terminal 522 - 593 IPR000961
domain Protein kinase C-like, phorbol ester/diacylglycerol-binding domain 140 - 192 IPR002219
active_site Serine/threonine-protein kinase, active site 373 - 385 IPR008271
binding_site Protein kinase, ATP binding site 259 - 286 IPR017441
domain Protein kinase, C-terminal 545 - 583 IPR017892
domain Diacylglycerol/phorbol-ester binding 138 - 152 IPR020454-1
domain Diacylglycerol/phorbol-ester binding 154 - 163 IPR020454-2
domain Diacylglycerol/phorbol-ester binding 167 - 178 IPR020454-3
domain Diacylglycerol/phorbol-ester binding 179 - 191 IPR020454-4
domain Atypical protein kinase C iota type, catalytic domain 232 - 595 IPR034661
domain Protein kinase C, PB1 domain 26 - 108 IPR034877
domain PB1-like domain 25 - 108 IPR053793

Functions

Description
EC Number 2.7.10.1 Protein-tyrosine kinases
Subcellular Localization
  • Cell membrane ; Single-pass type I membrane protein
  • Early endosome membrane ; Single-pass type I membrane protein
  • Late endosome membrane ; Single-pass type I membrane protein
  • Recycling endosome membrane ; Single-pass type I membrane protein
  • Internalized to endosomes upon binding of NGF or NTF3 and further transported to the cell body via a retrograde axonal transport
  • Localized at cell membrane and early endosomes before nerve growth factor (NGF) stimulation (PubMed:17724123, PubMed:26446845)
  • Recruited to late endosomes after NGF stimulation (PubMed:17724123, PubMed:26446845)
  • Colocalized with RAPGEF2 at late endosomes (PubMed:17724123)
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category No pathway information available

6 GO annotations of cellular component

Name Definition
cytoplasm The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures.
cytosol The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes.
Golgi apparatus A membrane-bound cytoplasmic organelle of the endomembrane system that further processes the core oligosaccharides (e.g. N-glycans) added to proteins in the endoplasmic reticulum and packages them into membrane-bound vesicles. The Golgi apparatus operates at the intersection of the secretory, lysosomal, and endocytic pathways.
Golgi membrane The lipid bilayer surrounding any of the compartments of the Golgi apparatus.
trans-Golgi network The network of interconnected tubular and cisternal structures located within the Golgi apparatus on the side distal to the endoplasmic reticulum, from which secretory vesicles emerge. The trans-Golgi network is important in the later stages of protein secretion where it is thought to play a key role in the sorting and targeting of secreted proteins to the correct destination.
trans-Golgi network membrane The lipid bilayer surrounding any of the compartments that make up the trans-Golgi network.

6 GO annotations of molecular function

Name Definition
enzyme activator activity Binds to and increases the activity of an enzyme.
GTP binding Binding to GTP, guanosine triphosphate.
GTPase activity Catalysis of the reaction
metal ion binding Binding to a metal ion.
phospholipase D activator activity Binds to and increases the activity of the enzyme phospholipase D.
protein domain specific binding Binding to a specific domain of a protein.

6 GO annotations of biological process

Name Definition
Golgi organization A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the Golgi apparatus.
intracellular protein transport The directed movement of proteins in a cell, including the movement of proteins between specific compartments or structures within a cell, such as organelles of a eukaryotic cell.
protein localization to Golgi apparatus A process in which a protein is transported to, or maintained in, a location within the Golgi apparatus.
retrograde transport, endosome to Golgi The directed movement of membrane-bounded vesicles from endosomes back to the trans-Golgi network where they are recycled for further rounds of transport.
toxin metabolic process The chemical reactions and pathways involving a toxin, a poisonous compound (typically a protein) that is produced by cells or organisms and that can cause disease when introduced into the body or tissues of an organism.
vesicle-mediated transport A cellular transport process in which transported substances are moved in membrane-bounded vesicles; transported substances are enclosed in the vesicle lumen or located in the vesicle membrane. The process begins with a step that directs a substance to the forming vesicle, and includes vesicle budding and coating. Vesicles are then targeted to, and fuse with, an acceptor membrane.

14 homologous proteins in AiPD

UniProt AC Gene Name Protein Name Species Evidence Code
Q8N4G2 ARL14 ADP-ribosylation factor-like protein 14 Homo sapiens (Human) SS
Q969Q4 ARL11 ADP-ribosylation factor-like protein 11 Homo sapiens (Human) PR
Q8IVW1 ARL17A ADP-ribosylation factor-like protein 17 Homo sapiens (Human) SS
P49703 ARL4D ADP-ribosylation factor-like protein 4D Homo sapiens (Human) PR
P62330 ARF6 ADP-ribosylation factor 6 Homo sapiens (Human) EV
Q9H0F7 ARL6 ADP-ribosylation factor-like protein 6 Homo sapiens (Human) SS
P18085 ARF4 ADP-ribosylation factor 4 Homo sapiens (Human) EV
P84085 ARF5 ADP-ribosylation factor 5 Homo sapiens (Human) EV
P61204 ARF3 ADP-ribosylation factor 3 Homo sapiens (Human) EV
P84077 ARF1 ADP-ribosylation factor 1 Homo sapiens (Human) EV
Q9Y689 ARL5A ADP-ribosylation factor-like protein 5A Homo sapiens (Human) SS
A6NH57 ARL5C Putative ADP-ribosylation factor-like protein 5C Homo sapiens (Human) SS
Q96KC2 ARL5B ADP-ribosylation factor-like protein 5B Homo sapiens (Human) SS
P40940 ARF3 ADP-ribosylation factor 3 Arabidopsis thaliana (Mouse-ear cress) SS
10 20 30 40 50 60
MLRGQRHGQL GWHRPAAGLG GLVTSLMLAC ACAASCRETC CPVGPSGLRC TRAGTLNTLR
70 80 90 100 110 120
GLRGAGNLTE LYVENQRDLQ RLEFEDLQGL GELRSLTIVK SGLRFVAPDA FHFTPRLSHL
130 140 150 160 170 180
NLSSNALESL SWKTVQGLSL QDLTLSGNPL HCSCALLWLQ RWEQEDLCGV YTQKLQGSGS
190 200 210 220 230 240
GDQFLPLGHN NSCGVPSVKI QMPNDSVEVG DDVFLQCQVE GQALQQADWI LTELEGTATM
250 260 270 280 290 300
KKSGDLPSLG LTLVNVTSDL NKKNVTCWAE NDVGRAEVSV QVSVSFPASV HLGKAVEQHH
310 320 330 340 350 360
WCIPFSVDGQ PAPSLRWFFN GSVLNETSFI FTQFLESALT NETMRHGCLR LNQPTHVNNG
370 380 390 400 410 420
NYTLLAANPY GQAAASIMAA FMDNPFEFNP EDPIPVSFSP VDTNSTSRDP VEKKDETPFG
430 440 450 460 470 480
VSVAVGLAVS AALFLSALLL VLNKCGQRSK FGINRPAVLA PEDGLAMSLH FMTLGGSSLS
490 500 510 520 530 540
PTEGKGSGLQ GHIMENPQYF SDTCVHHIKR QDIILKWELG EGAFGKVFLA ECYNLLNDQD
550 560 570 580 590 600
KMLVAVKALK ETSENARQDF HREAELLTML QHQHIVRFFG VCTEGGPLLM VFEYMRHGDL
610 620 630 640 650 660
NRFLRSHGPD AKLLAGGEDV APGPLGLGQL LAVASQVAAG MVYLASLHFV HRDLATRNCL
670 680 690 700 710 720
VGQGLVVKIG DFGMSRDIYS TDYYRVGGRT MLPIRWMPPE SILYRKFSTE SDVWSFGVVL
730 740 750 760 770 780
WEIFTYGKQP WYQLSNTEAI ECITQGRELE RPRACPPDVY AIMRGCWQRE PQQRLSMKDV
790
HARLQALAQA PPSYLDVLG